Shanghai ZJ Bio-Tech Co. Ltd. A Cash Flow Conversion Efficiency
Shanghai ZJ Bio-Tech Co. Ltd. A cash flow conversion efficiency. Based on the latest financial reports, Shanghai ZJ Bio-Tech Co. Ltd. A (688317) has a cash flow conversion efficiency ratio of 0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥6.85 Million ≈ $1.00 Million USD) by net assets (CN¥3.39 Billion ≈ $496.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2025)
Cash flow conversion efficiency of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2025. This chart illustrates how Shanghai ZJ Bio-Tech Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 688317 share price today for real-time trading data and today's change.
Shanghai ZJ Bio-Tech Co. Ltd. A Cash Flow Conversion Ratio Explained
Shanghai ZJ Bio-Tech Co. Ltd. A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shanghai ZJ Bio-Tech Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai ZJ Bio-Tech Co. Ltd. A ranked by their cash flow conversion efficiency. Also see Shanghai ZJ Bio-Tech Co. Ltd. A (688317) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shinhan Alpha REIT Co Ltd
KO:293940
|
0.005x |
|
Yieh United Steel
TWO:9957
|
-0.055x |
|
Guggenheim Active Allocation Fund
NYSE:GUG
|
N/A |
|
Concord Securities Co Ltd
TWO:6016
|
-0.162x |
|
One Liberty Properties Inc
NYSE:OLP
|
0.015x |
|
RPG Life Sciences Limited
NSE:RPGLIFE
|
0.019x |
|
Hanssem
KO:009240
|
0.096x |
|
Zhongrui Co Ltd
SHE:301587
|
0.017x |
Annual Cash Flow Conversion Efficiency for Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2025. Review Shanghai ZJ Bio-Tech Co. Ltd. A (688317) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.35 Billion ≈ $490.04 Million |
CN¥66.85 Million ≈ $9.78 Million |
0.020x | -6.43% |
| 2024-12-31 | CN¥3.64 Billion ≈ $532.19 Million |
CN¥77.59 Million ≈ $11.35 Million |
0.021x | +199.65% |
| 2023-12-31 | CN¥3.82 Billion ≈ $559.71 Million |
CN¥-81.88 Million ≈ $-11.98 Million |
-0.021x | -115.37% |
| 2022-12-31 | CN¥4.20 Billion ≈ $614.65 Million |
CN¥584.97 Million ≈ $85.60 Million |
0.139x | -16.97% |
| 2021-12-31 | CN¥3.83 Billion ≈ $560.07 Million |
CN¥641.94 Million ≈ $93.94 Million |
0.168x | -78.52% |
| 2020-12-31 | CN¥1.46 Billion ≈ $214.02 Million |
CN¥1.14 Billion ≈ $167.08 Million |
0.781x | +482.33% |
| 2019-12-31 | CN¥571.84 Million ≈ $83.68 Million |
CN¥76.66 Million ≈ $11.22 Million |
0.134x | -11.44% |
| 2018-12-31 | CN¥532.66 Million ≈ $77.95 Million |
CN¥80.63 Million ≈ $11.80 Million |
0.151x | +49.06% |
| 2017-12-31 | CN¥472.70 Million ≈ $69.17 Million |
CN¥48.00 Million ≈ $7.02 Million |
0.102x | +10.36% |
| 2016-12-31 | CN¥483.90 Million ≈ $70.81 Million |
CN¥44.53 Million ≈ $6.52 Million |
0.092x | +147.38% |
| 2015-12-31 | CN¥343.47 Million ≈ $50.26 Million |
CN¥12.78 Million ≈ $1.87 Million |
0.037x | -85.11% |
| 2014-12-31 | CN¥110.35 Million ≈ $16.15 Million |
CN¥27.57 Million ≈ $4.03 Million |
0.250x | +4.71% |
| 2013-12-31 | CN¥118.03 Million ≈ $17.27 Million |
CN¥28.16 Million ≈ $4.12 Million |
0.239x | -- |
About Shanghai ZJ Bio-Tech Co. Ltd. A
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. The company offers nucleic acid and real-time PCR kits, as well as consumables. It serves public health safety and clinical diagnostics sectors. The company was founded in 2005 and is based in Shanghai, China.